Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Lundbeck's Vyepti (eptinezumab) receives South Korea marketing authorization for preventive migraine treatment
Antibody, neurological, monoclonal antibody, migraine, CGRP target, preventive treatment - Read more

Apogee Therapeutics, Blackstone Life Sciences seal $1.3B royalty financing deal for eczema drug zumilokibart phase 3
Royalty financing, autoimmune, antibody, milestone payments, commercialization - Read more

AGC Biologics, Teikoku Seiyaku partner on microbial CDMO services for rhMMP-7 lumbar disc herniation therapy
Manufacturing agreement, musculoskeletal, biologics, R&D, clinical trials - Read more

Insilico Medicine, Human Life Foundation Models partner on multi-million-dollar ageing AI foundation models
Research collaboration, AI/ML, drug discovery, ageing/longevity, digital health, milestone payments - Read more

Merz Therapeutics, Kvvit Pharmaceutical partner on exclusive INBRIJA® license for Greater China, upfront and milestone payments
Licensing deal, neurological, small molecule, commercialization, milestone payments, royalties - Read more

ZBD Pharmaceutical, Zhejiang Teruisi sign 10-year exclusive China distribution deal for CD20-targeting ADC TRS005
Distribution agreement, oncology, antibody-drug conjugate, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Junshi Biosciences' toripalimab meets Ph3 primary endpoints for resectable stage II-III non-small cell lung cancer perioperative treatment
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, PD-1 inhibitor, perioperative therapy - Read more

Kardigan plans IPO to advance late-stage cardiovascular pipeline with three assets
Cardiovascular, small molecule, antisense oligonucleotide, clinical-stage - Read more

MindMaze Therapeutics raises CHF 8M ($10.2M) strategic equity financing, scaling U.S. neurotherapeutics deployment
Neurological, digital therapeutics, AI-driven, platform technology - Read more

Editas Medicine raises $125M, plans up to $319.4M total through warrant exercises
CRISPR, gene therapy, cardiovascular, preclinical - Read more

Cartesian Therapeutics secures $150M credit facility, extending cash runway into 2028
Autoimmune, cell therapy, CAR-T, clinical-stage, myasthenia gravis - Read more

Ysios Capital launches InceptionBio, €100M ($116.36) biotech fund targeting early-stage Spanish companies
Venture capital, life sciences, early-stage, technology transfer - Read more

Synakis Corp. closes CAD $2.6M ($1.88M) pre-seed funding for ocular retinal disease therapies
Ocular disease, retinal disease, glaucoma, platform technology, preclinical - Read more

Olympus acquires BioProtect for $270M, adding biodegradable balloon spacer technology for prostate cancer radiation therapy
Medical device, oncology, strategic, major transaction - Read more

Outlook Therapeutics' Lytenava (bevacizumab) gains FDA appeal win for wet age-related macular degeneration
Antibody, ophthalmology, monoclonal antibody, wet age-related macular degeneration, bevacizumab, VEGF inhibitor - Read more

FDA convenes vaccine experts to evaluate updating COVID-19 formulation to target dominant XFG subvariant
mRNA vaccine, infectious disease, regulatory, competitive - Read more

Astellas unveils five-year growth strategy to offset Xtandi patent expiry through pipeline acquisitions
Small molecule, oncology, strategic, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Biogen investigated by Italian regulator over alleged market abuse tied to multiple sclerosis drug Tysabri
Monoclonal antibody, neurological, competitive, regulatory - Read more

AstraZeneca's (camizestrant) FDA review delayed after advisory committee rejects Ph3 data for HR-positive breast cancer
Small molecule, cancer, oral SERD, breast cancer, ESR1 mutation, HR-positive breast cancer - Read more

FDA's Makary-era reforms, including CNPV program, to continue despite commissioner's resignation and leadership turnover
Regulatory reform, operational, strategic - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here